Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen
- 1 August 1989
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 10 (2), 198-202
- https://doi.org/10.1002/hep.1840100213
Abstract
The course of chronic hepatitis B was studied in 30 patients who had antibody to hepatitis e antigen and hepatitis B virus DNA in the serum and hepatitis B core antigen in the liver. Over a 2-year period, no patient experienced a sustained spontaneous remission of disease, and follow-up liver histology revealed worsening of the disease in four patients. After 2 years of observation, 24 patients were allocated randomly to one of two groups: 12 patients served as untreated controls and 12 received recombinant human α-interferon-2a in a dose of 9 million units intramuscularly three times weekly for 16 weeks. Patients who remained viremic after 16 weeks received 3 million units three times weekly for an additional 8 weeks. Abnormal aminotransferases and serum hepatitis B virus DNA persisted without appreciable changes in all untreated patients. Hepatitis B virus DNA rapidly became undetectable and serum aminotransferases fell to normal in eight treated patients. After the end of treatment, hepatitis B virus DNA became detectable once again in seven patients, in six of whom a peak of aminotransferases (range: 256 to 850 units per liter) ensued; subsequently, hepatitis B virus DNA disappeared, and serum aminotransferases again fell to normal in two of the seven. Overall, hepatitis B virus DNA was no longer detectable in serum and liver histology improved in three treated patients. These results suggest that chronic hepatitis B with anti-HBe in serum differs from chronic hepatitis with HBeAg in both natural history and response to interferon. Peculiar features are the frequency of spontaneous remissions and a high frequency of reactivation after a response to interferon. New and more effective schedules of antiviral treatment are needed for this subset of patients with chronic hepatitis B.This publication has 13 references indexed in Scilit:
- The importance of hepatitis B viral DNA in serum and liverJournal of Hepatology, 1986
- Natural history of chronic hepatitis B virus-related liver disease and its relationship to serum markers of viral replicationJournal of Hepatology, 1986
- Chronic hepatitis in HBsAg carriers with serum HBV-DNA and Anti-HBeGastroenterology, 1986
- Viral HepatitisProceedings in Life Sciences, 1986
- TREATMENT OF CHRONIC HEPATITIS DUE TO HEPATITIS B VIRUSThe Lancet, 1985
- Recombinant Leukocyte Interferon Treatment of Chronic Hepatitis BHepatology, 1985
- Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection.Gut, 1984
- Analysis of Liver Disease, Nuclear HBcAg, Viral Replication, and Hepatitis B Virus DNA in Liver and Serum of HBcAg Vs. Anti-HBe Positive Carriers of Hepatitis B VirusHepatology, 1983
- Chronic Type B HepatitisGastroenterology, 1983
- Hepatitis B virus DNA in the sera of HBsAg carriers: A marker of active hepatitis B virus replication in the liverHepatology, 1981